According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
_256_384.jpg)
The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings
Ind-Ra expects FY22 IPM to have witnessed 15% YoY sales growth, higher than the 8%-10% observed over the past five years, aided by the base effect
Ind-Ra expects revenue growth of over 12% in 2022.
_256_384.jpg)
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
Ind-Ra continues to expect IPM’s revenue to grow over 12% yoy in FY22
Post normalisation of high growth months of April and May this year the average IPM growth from June to August this year stood at 15.2 % YoY : Ind-Ra reports
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
Demand normalisation post the second wave contributed to the steady growth
Subscribe To Our Newsletter & Stay Updated
